However, in the high HSP90α group the patients had older median age, more aggressive baseline BCLC stage, reduced liver function, and elevated tumor burden (p < 0.05), compared with the low HSP90α group (Table 1). This evidence concerns the gene HSP90AA1 and neoplasm.